Suggestions
Steve Schwartz
Co-founder, CTO at Genomenon Inc.
Steve Schwartz is a prominent figure in the tech and genomics sectors, known for his role as co-founder and former Chief Technology Officer (CTO) of Genomenon, a company that specializes in genome interpretation software. He has a strong background in engineering and software development, having transitioned from a Mechanical/Electrical Engineering focus to founding and advising multiple startups over nearly two decades.
Professional Background
- Genomenon: Schwartz co-founded Genomenon in 2014, where he played a crucial role in developing AI-driven software aimed at aiding clinical sequencing labs in diagnosing cancer and rare diseases. The company has successfully raised over $30 million in funding and expanded to 150 employees across the US and Europe. In 2023, Genomenon was acquired by Boston Genetics.124
- Alfa Jango: He is also the founder of Alfa Jango, a company that focuses on software development and technical consulting.15
- Carcode: Prior to his work at Genomenon, Schwartz was co-founder and CTO of Carcode, which was acquired by Edmunds.com in 2014.13
Skills and Contributions
Schwartz is recognized for his expertise in building technical teams and developing innovative software solutions. He has authored open-source software that has garnered hundreds of millions of downloads. His work emphasizes the intersection of technology and healthcare, particularly in improving genomic data accessibility for researchers and clinicians.24
Current Endeavors
In addition to his roles at Genomenon and Alfa Jango, Schwartz invests in startups, advises founders, and speaks on topics related to technology startups, software development, and artificial intelligence. His contributions to the tech community include insights on navigating challenges in clinical genomics and fostering innovation within the industry.136
Steve Schwartz's career reflects a commitment to leveraging technology for significant advancements in healthcare, particularly through genomic research and precision medicine.

